| Year |
Citation |
Score |
| 2024 |
Rizk MM, Bolton L, Cathomas F, He H, Russo SJ, Guttman-Yassky E, Mann JJ, Murrough J. Immune-Targeted Therapies for Depression: Current Evidence for Antidepressant Effects of Monoclonal Antibodies. The Journal of Clinical Psychiatry. 85. PMID 38959503 DOI: 10.4088/JCP.23nr15243 |
0.401 |
|
| 2024 |
Rizk MM, Murrough JW. Ketamine, Dissociation, and Depression: What Is "Special" About Ketamine? (Revisited). The International Journal of Neuropsychopharmacology. 27. PMID 38864154 DOI: 10.1093/ijnp/pyae024 |
0.336 |
|
| 2024 |
Hines LJ, Wilke RA, Myers R, Mathews CA, Liu M, Baye JF, Petry N, Cicali EJ, Duong BQ, Elwood E, Hulvershorn L, Nguyen K, Ramos M, Sadeghpour A, Wu RR, ... ... Murrough JW, et al. Rationale and design for a pragmatic randomized trial to assess gene-based prescribing for SSRIs in the treatment of depression. Clinical and Translational Science. 17: e13822. PMID 38860639 DOI: 10.1111/cts.13822 |
0.311 |
|
| 2024 |
Gharios C, van Leent MMT, Chang HL, Abohashem S, O'Connor D, Osborne MT, Tang CY, Kaufman AE, Robson PM, Ramachandran S, Calcagno C, Mani V, Trivieri MG, Seligowski AV, Dekel S, ... ... Murrough JW, et al. Cortico-limbic interactions and carotid atherosclerotic burden during chronic stress exposure. European Heart Journal. 45: 1753-1764. PMID 38753456 DOI: 10.1093/eurheartj/ehae149 |
0.534 |
|
| 2023 |
McIntyre RS, Alsuwaidan M, Baune BT, Berk M, Demyttenaere K, Goldberg JF, Gorwood P, Ho R, Kasper S, Kennedy SH, Ly-Uson J, Mansur RB, McAllister-Williams RH, Murrough JW, Nemeroff CB, et al. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry : Official Journal of the World Psychiatric Association (Wpa). 22: 394-412. PMID 37713549 DOI: 10.1002/wps.21120 |
0.314 |
|
| 2023 |
Yang EJ, Frolinger T, Iqbal UH, Murrough J, Pasinetti GM. The Bioactive Dietary Polyphenol Preparation Alleviates Depression and Anxiety-Like Behaviors by Modulating the Regional Heterogeneity of Microglia Morphology. Molecular Nutrition & Food Research. e2300156. PMID 37439457 DOI: 10.1002/mnfr.202300156 |
0.315 |
|
| 2023 |
Anand A, Mathew SJ, Sanacora G, Murrough JW, Goes FS, Altinay M, Aloysi AS, Asghar-Ali AA, Barnett BS, Chang LC, Collins KA, Costi S, Iqbal S, Jha MK, Krishnan K, et al. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. The New England Journal of Medicine. PMID 37224232 DOI: 10.1056/NEJMoa2302399 |
0.327 |
|
| 2023 |
Yang EJ, Frolinger T, Westfall S, Iqbal UH, Murrough J, Pasinetti GM. The bioactive dietary polyphenol preparation alleviates depression and anxiety-like behaviors by modulating the regional heterogeneity of microglia morphology. Biorxiv : the Preprint Server For Biology. PMID 37034623 DOI: 10.1101/2023.03.30.534961 |
0.315 |
|
| 2023 |
Alper J, Feng R, Verma G, Rutter S, Huang KH, Xie L, Yushkevich P, Jacob Y, Brown S, Kautz M, Schneider M, Lin HM, Fleysher L, Delman BN, Hof PR, ... Murrough JW, et al. Stress-related reduction of hippocampal subfield volumes in major depressive disorder: A 7-Tesla study. Frontiers in Psychiatry. 14: 1060770. PMID 36816419 DOI: 10.3389/fpsyt.2023.1060770 |
0.404 |
|
| 2022 |
Hock RS, Feeney A, Iovieno N, Murrough JW, Mathew SJ, Iosifescu DV, Fava M, Jha MK, Papakostas GI. Rapidity of Symptom Improvement With Intranasal Esketamine for Major Depressive Disorder: A Systematic Review and Meta-Analysis. The Journal of Clinical Psychiatry. 84. PMID 36516320 DOI: 10.4088/JCP.21r14086 |
0.346 |
|
| 2022 |
Price RB, Kissel N, Baumeister A, Rohac R, Woody ML, Ballard ED, Zarate CA, Deakin W, Abdallah CG, Feder A, Charney DS, Grunebaum MF, Mann JJ, Mathew SJ, Gallagher B, ... ... Murrough JW, et al. International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators. Molecular Psychiatry. PMID 36071111 DOI: 10.1038/s41380-022-01757-7 |
0.382 |
|
| 2022 |
Bloomfield-Clagett B, Ballard ED, Greenstein DK, Wilkinson ST, Grunebaum MF, Murrough JW, Mathew SJ, Phillips JL, Fava M, Sanacora G, Zarate CA. A Participant-Level Integrative Data Analysis of Differential Placebo Response for Suicidal Ideation and Non-Suicidal Depressive Symptoms in Clinical Trials of Intravenous Racemic Ketamine. The International Journal of Neuropsychopharmacology. PMID 35994774 DOI: 10.1093/ijnp/pyac055 |
0.305 |
|
| 2022 |
Evers AG, Murrough JW, Charney DS, Costi S. Ketamine as a prophylactic resilience-enhancing agent. Frontiers in Psychiatry. 13: 833259. PMID 35966469 DOI: 10.3389/fpsyt.2022.833259 |
0.401 |
|
| 2022 |
Boukezzi S, Costi S, Shin LM, Kim-Schulze S, Cathomas F, Collins A, Russo SJ, Morris LS, Murrough JW. Exaggerated Amygdala Response to Threat and Association with Immune Hyperactivity in Depression. Brain, Behavior, and Immunity. PMID 35636614 DOI: 10.1016/j.bbi.2022.05.015 |
0.627 |
|
| 2022 |
Klein ME, Grice AB, Sheth S, Go M, Murrough JW. Pharmacological Treatments for Anhedonia. Current Topics in Behavioral Neurosciences. PMID 35507281 DOI: 10.1007/7854_2022_357 |
0.347 |
|
| 2022 |
Costi S, Han MH, Murrough JW. The Potential of KCNQ Potassium Channel Openers as Novel Antidepressants. Cns Drugs. 36: 207-216. PMID 35258812 DOI: 10.1007/s40263-021-00885-y |
0.343 |
|
| 2022 |
Evers A, Klein M, Aloysi A, Murrough J, Jha MK. Antidepressant effect of prolonged twice-weekly intranasal esketamine treatments after nonresponse to electroconvulsive therapy in a patient with treatment-resistant depression. Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists. 34: 61-64. PMID 35166666 DOI: 10.12788/acp.0055 |
0.312 |
|
| 2021 |
Costi S, Morris LS, Collins A, Fernandez NF, Patel M, Xie H, Kim-Schulze S, Stern ER, Collins KA, Cathomas F, Parides MK, Whitton AE, Pizzagalli DA, Russo SJ, Murrough JW. Peripheral immune cell reactivity and neural response to reward in patients with depression and anhedonia. Translational Psychiatry. 11: 565. PMID 34741019 DOI: 10.1038/s41398-021-01668-1 |
0.327 |
|
| 2021 |
Norbury A, Rutter SB, Collins AB, Costi S, Jha MK, Horn SR, Kautz M, Corniquel M, Collins KA, Glasgow AM, Brallier J, Shin LM, Charney DS, Murrough JW, Feder A. Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: preliminary evidence. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 34333555 DOI: 10.1038/s41386-021-01104-4 |
0.579 |
|
| 2021 |
Iovieno N, Papakostas GI, Feeney A, Fava M, Mathew SJ, Iosifescu DI, Murrough JW, Macaluso M, Hock RS, Jha MK. Vortioxetine Versus Placebo for Major Depressive Disorder: A Comprehensive Analysis of the Clinical Trial Dataset. The Journal of Clinical Psychiatry. 82. PMID 34133089 DOI: 10.4088/JCP.20r13682 |
0.361 |
|
| 2021 |
McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, Brietzke E, Dodd S, Gorwood P, Ho R, Iosifescu DV, Lopez Jaramillo C, Kasper S, Kratiuk K, Lee JG, et al. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. The American Journal of Psychiatry. appiajp202020081251. PMID 33726522 DOI: 10.1176/appi.ajp.2020.20081251 |
0.386 |
|
| 2021 |
Costi S, Morris LS, Kirkwood KA, Hoch M, Corniquel M, Vo-Le B, Iqbal T, Chadha N, Pizzagalli DA, Whitton A, Bevilacqua L, Jha MK, Ursu S, Swann AC, Collins KA, ... ... Murrough JW, et al. Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial. The American Journal of Psychiatry. appiajp202020050653. PMID 33653118 DOI: 10.1176/appi.ajp.2020.20050653 |
0.313 |
|
| 2021 |
Soogrim V, Ruberto VL, Murrough J, Jha MK. Spotlight on Pimavanserin Tartrate and Its Therapeutic Potential in the Treatment of Major Depressive Disorder: The Evidence to Date. Drug Design, Development and Therapy. 15: 151-157. PMID 33469267 DOI: 10.2147/DDDT.S240862 |
0.388 |
|
| 2020 |
Rivas-Grajales AM, Salas R, Robinson ME, Qi K, Murrough JW, Mathew SJ. Habenula connectivity and intravenous ketamine in treatment-resistant depression. The International Journal of Neuropsychopharmacology. PMID 33249434 DOI: 10.1093/ijnp/pyaa089 |
0.385 |
|
| 2020 |
Mathé AA, Michaneck M, Berg E, Charney DS, Murrough JW. A Randomized Controlled Trial of Intranasal Neuropeptide Y in Patients With Major Depressive Disorder. The International Journal of Neuropsychopharmacology. PMID 33009815 DOI: 10.1093/ijnp/pyaa054 |
0.39 |
|
| 2020 |
Averill LA, Fouda S, Murrough JW, Abdallah CG. Chronic stress pathology and ketamine-induced alterations in functional connectivity in major depressive disorder: An abridged review of the clinical evidence. Advances in Pharmacology (San Diego, Calif.). 89: 163-194. PMID 32616206 DOI: 10.1016/Bs.Apha.2020.04.003 |
0.493 |
|
| 2020 |
Pizzagalli DA, Smoski M, Ang YS, Whitton AE, Sanacora G, Mathew SJ, Nurnberger J, Lisanby SH, Iosifescu DV, Murrough JW, Yang H, Weiner RD, Calabrese JR, Goodman W, Potter WZ, et al. Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS). Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 32544925 DOI: 10.1038/S41386-020-0738-4 |
0.335 |
|
| 2020 |
Nasca C, Dobbin J, Bigio B, Watson K, de Angelis P, Kautz M, Cochran A, Mathé AA, Kocsis JH, Lee FS, Murrough JW, McEwen BS, Rasgon N. Insulin receptor substrate in brain-enriched exosomes in subjects with major depression: on the path of creation of biosignatures of central insulin resistance. Molecular Psychiatry. PMID 32536688 DOI: 10.1038/S41380-020-0804-7 |
0.326 |
|
| 2020 |
Ruberto VL, Jha MK, Murrough JW. Pharmacological Treatments for Patients with Treatment-Resistant Depression. Pharmaceuticals (Basel, Switzerland). 13. PMID 32512768 DOI: 10.3390/Ph13060116 |
0.46 |
|
| 2020 |
Papakostas GI, Salloum NC, Hock RS, Jha MK, Murrough JW, Mathew SJ, Iosifescu DV, Fava M. Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis. The Journal of Clinical Psychiatry. 81. PMID 32459407 DOI: 10.4088/Jcp.19R12889 |
0.479 |
|
| 2020 |
Krystal AD, Pizzagalli DA, Smoski M, Mathew SJ, Nurnberger J, Lisanby SH, Iosifescu D, Murrough JW, Yang H, Weiner RD, Calabrese JR, Sanacora G, Hermes G, Keefe RSE, Song A, et al. A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia. Nature Medicine. PMID 32231295 DOI: 10.1038/S41591-020-0806-7 |
0.358 |
|
| 2020 |
Morris LS, Tan A, Smith DA, Grehl M, Han-Huang K, Naidich TP, Charney DS, Balchandani P, Murrough JW, Kundu P. Sub-millimeter variation in human locus coeruleus is associated with dimensional measures of psychopathology: An in vivo ultra-high field 7-Tesla MRI study. Neuroimage. Clinical. 25: 102148. PMID 32097890 DOI: 10.1016/J.Nicl.2019.102148 |
0.623 |
|
| 2020 |
Morris LS, Costi S, Tan A, Stern ER, Charney D, Murrough JW. Ketamine normalizes subgenual cingulate cortex hyper-activity in depression. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 31896116 DOI: 10.1038/S41386-019-0591-5 |
0.682 |
|
| 2020 |
Jacob Y, Morris L, Huang K, Schneider M, Rutter S, Verma G, Murrough JW, Balchandani P. Classification Between Major Depressive Disorder and Healthy Controls Using Functional Brain Network Topology Biological Psychiatry. 87: S260. DOI: 10.1016/J.Biopsych.2020.02.673 |
0.426 |
|
| 2020 |
Verma G, Jacob Y, Morris L, Murrough J, Balchandani P. Brain Age Modeling Using High-Resolution 7T MR Imaging and Implications in Major Depressive Disorder Biological Psychiatry. 87: S257. DOI: 10.1016/J.Biopsych.2020.02.665 |
0.403 |
|
| 2020 |
Bevilacqua L, Cathomas F, Ramakrishnan A, Schneider M, Shen L, Russo S, Murrough J. Gene Expression and Molecular Pathways Associated With Rapid Antidepressant Response to Ketamine in Patients With Treatment Resistant Depression Biological Psychiatry. 87: S176-S177. DOI: 10.1016/j.biopsych.2020.02.465 |
0.302 |
|
| 2020 |
Bevilacqua L, Cathomas F, Ramakrishnan A, Shen L, Russo S, Murrough J. Gene Expression and Molecular Pathways Associated With Rapid Antidepressant Response to Ketamine in Patients With Treatment Resistant Depression Biological Psychiatry. 87: S16. DOI: 10.1016/J.Biopsych.2020.02.067 |
0.414 |
|
| 2020 |
Murrough J, Costi S, Morris L, Collins A, Collins K, Whitton A, Pizzagalli D, Russo S. Dynamic Peripheral Immune Profiles and Neurocircuit Responses to Reward in Depression Biological Psychiatry. 87: S15-S16. DOI: 10.1016/J.Biopsych.2020.02.066 |
0.367 |
|
| 2019 |
Hoch MM, Doucet GE, Moser DA, Hee Lee W, Collins KA, Huryk KM, DeWilde KE, Fleysher L, Iosifescu DV, Murrough JW, Charney DS, Frangou S, Iacoviello BM. Initial Evidence for Brain Plasticity Following a Digital Therapeutic Intervention for Depression. Chronic Stress (Thousand Oaks, Calif.). 3: 2470547019877880. PMID 32440602 DOI: 10.1177/2470547019877880 |
0.335 |
|
| 2019 |
Jha MK, Murrough JW. Psychopharmacology and Experimental Therapeutics for Bipolar Depression. Focus (American Psychiatric Publishing). 17: 232-237. PMID 32047368 DOI: 10.1176/appi.focus.20190009 |
0.366 |
|
| 2019 |
Jacob Y, Morris LS, Huang KH, Schneider M, Rutter S, Verma G, Murrough JW, Balchandani P. Neural correlates of rumination in major depressive disorder: A brain network analysis. Neuroimage. Clinical. 25: 102142. PMID 31901654 DOI: 10.1016/J.Nicl.2019.102142 |
0.36 |
|
| 2019 |
Witt K, Potts J, Hubers A, Grunebaum MF, Murrough JW, Loo C, Cipriani A, Hawton K. Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials. The Australian and New Zealand Journal of Psychiatry. 4867419883341. PMID 31729893 DOI: 10.1177/0004867419883341 |
0.371 |
|
| 2019 |
Janiri D, Moser DA, Doucet GE, Luber MJ, Rasgon A, Lee WH, Murrough JW, Sani G, Eickhoff SB, Frangou S. Shared Neural Phenotypes for Mood and Anxiety Disorders: A Meta-analysis of 226 Task-Related Functional Imaging Studies. Jama Psychiatry. 1-8. PMID 31664439 DOI: 10.1001/Jamapsychiatry.2019.3351 |
0.414 |
|
| 2019 |
Citrome L, Gaynes BN, Goldberg JF, Ketter T, Murrough JW. New Mechanisms, New Opportunities: Integrating Novel Antidepressants in the Treatment of Major Depressive Disorder. The Journal of Clinical Psychiatry. 80. PMID 31365193 DOI: 10.4088/Jcp.Tk18061As2C |
0.484 |
|
| 2019 |
Woods AG, Wormwood KL, Iosifescu DV, Murrough J, Darie CC. Protein Biomarkers in Major Depressive Disorder: An Update. Advances in Experimental Medicine and Biology. 1140: 585-600. PMID 31347073 DOI: 10.1007/978-3-030-15950-4_35 |
0.409 |
|
| 2019 |
Lewis S, Romano C, De Bruecker G, Murrough JW, Shelton R, Singh JB, Jamieson C. Analysis of Clinical Trial Exit Interview Data in Patients with Treatment-Resistant Depression. The Patient. PMID 31270774 DOI: 10.1007/S40271-019-00369-8 |
0.376 |
|
| 2019 |
Cathomas F, Murrough JW, Nestler EJ, Han MH, Russo SJ. Neurobiology of Resilience: Interface Between Mind and Body. Biological Psychiatry. PMID 31178098 DOI: 10.1016/J.Biopsych.2019.04.011 |
0.391 |
|
| 2019 |
Jha MK, Qamar A, Vaduganathan M, Charney DS, Murrough JW. Screening and Management of Depression in Patients With Cardiovascular Disease: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 73: 1827-1845. PMID 30975301 DOI: 10.1016/J.Jacc.2019.01.041 |
0.408 |
|
| 2019 |
Costi S, Soleimani L, Glasgow A, Brallier J, Spivack J, Schwartz J, Levitch CF, Richards S, Hoch M, Wade E, Welch A, Collins KA, Feder A, Iosifescu DV, Charney DS, ... Murrough JW, et al. Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 30858518 DOI: 10.1038/S41386-019-0365-0 |
0.47 |
|
| 2019 |
Rutland JW, Brown S, Verma G, Feldman RE, Sharma H, Markowitz M, Schneider M, Delman BN, Murrough J, Balchandani P. Hippocampal subfield-specific connectivity findings in major depressive disorder: A 7 Tesla diffusion MRI study. Journal of Psychiatric Research. 111: 186-192. PMID 30798080 DOI: 10.1016/J.Jpsychires.2019.02.008 |
0.423 |
|
| 2019 |
Morris LS, Kundu P, Costi S, Collins A, Schneider M, Verma G, Balchandani P, Murrough JW. Ultra-high field MRI reveals mood-related circuit disturbances in depression: a comparison between 3-Tesla and 7-Tesla. Translational Psychiatry. 9: 94. PMID 30770788 DOI: 10.1038/S41398-019-0425-6 |
0.325 |
|
| 2019 |
Wilkinson ST, Farmer C, Ballard E, Mathew SJ, Grunebaum MF, Murrough JW, Sos P, Wang G, Gueorguieva R, Zarate CA. Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 30653192 DOI: 10.1038/S41386-019-0317-8 |
0.318 |
|
| 2019 |
Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, et al. Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Molecular Psychiatry. PMID 30617276 DOI: 10.1038/S41380-018-0311-2 |
0.367 |
|
| 2019 |
Oh KY, Van Dam NT, Doucette JT, Murrough JW. Effects of chronic physical disease and systemic inflammation on suicide risk in patients with depression: a hospital-based case-control study. Psychological Medicine. 1-9. PMID 30606276 DOI: 10.1017/S0033291718003902 |
0.654 |
|
| 2019 |
Morris L, Tan A, Smith D, Grehl M, Huang K, Naidich T, Kundu P, Murrough J. S8. Increased Locus Coeruleus Volume in Humans With Pathological Anxiety: An Ultra-High Field 7-Tesla MRI Study Biological Psychiatry. 85: S299-S300. DOI: 10.1016/J.Biopsych.2019.03.759 |
0.583 |
|
| 2019 |
Janiri D, Moser D, Doucet G, Luber M, Rasgon A, Lee W, Murrough J, Sani G, Eickhoff S, Frangou S. F124. Mapping the Neural Correlates of Mood and Anxiety Disorders Onto Research Domain Criteria: A Meta-Analysis of 226 Task-Related Functional Imaging Studies Biological Psychiatry. 85. DOI: 10.1016/J.Biopsych.2019.03.661 |
0.312 |
|
| 2019 |
Murrough J, Van Dam N, Grehl M, Tan A, Morris L. 132. Structural and Connectomic Brain Features of Treatment Resistant Depression and Antidepressant Response to Ketamine Biological Psychiatry. 85: S55. DOI: 10.1016/J.Biopsych.2019.03.146 |
0.653 |
|
| 2018 |
Mathew SJ, Wilkinson ST, Altinay M, Asghar-Ali A, Chang LC, Collins KA, Dale RM, Hu B, Krishnan K, Kellner CH, Malone DA, Murrough JW, Ostroff RB, Sanacora G, Shao M, et al. ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol. Contemporary Clinical Trials. PMID 30572160 DOI: 10.1016/J.Cct.2018.12.009 |
0.453 |
|
| 2018 |
Guo W, Machado-Vieira R, Mathew S, Murrough JW, Charney DS, Gruenbaum M, Oquendo MA, Kadriu B, Akula N, Henter I, Yuan P, Merikangas K, Drevets W, Furey M, Mann JJ, et al. Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression. Translational Psychiatry. 8: 280. PMID 30552317 DOI: 10.1038/S41398-018-0311-7 |
0.475 |
|
| 2018 |
Tan A, Costi S, Morris LS, Van Dam NT, Kautz M, Whitton AE, Friedman AK, Collins KA, Ahle G, Chadha N, Do B, Pizzagalli DA, Iosifescu DV, Nestler EJ, Han MH, ... Murrough JW, et al. Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorder. Molecular Psychiatry. PMID 30385872 DOI: 10.1038/S41380-018-0283-2 |
0.773 |
|
| 2018 |
Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, et al. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Molecular Psychiatry. PMID 30283029 DOI: 10.1038/S41380-018-0256-5 |
0.346 |
|
| 2018 |
Stern ER, Shahab R, Grimaldi SJ, Leibu E, Murrough JW, Fleysher L, Parides MK, Coffey BJ, Burdick KE, Goodman WK. High-dose ondansetron reduces activation of interoceptive and sensorimotor brain regions. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 30116006 DOI: 10.1038/S41386-018-0174-X |
0.331 |
|
| 2018 |
Nasca C, Bigio B, Lee FS, Young SP, Kautz MM, Albright A, Beasley J, Millington DS, Mathé AA, Kocsis JH, Murrough JW, McEwen BS, Rasgon N. Acetyl-l-carnitine deficiency in patients with major depressive disorder. Proceedings of the National Academy of Sciences of the United States of America. PMID 30061399 DOI: 10.1073/Pnas.1801609115 |
0.482 |
|
| 2018 |
Murrough JW, Huryk KM, Mao X, Iacoviello B, Collins K, Nierenberg AA, Kang G, Shungu DC, Iosifescu DV. A pilot study of minocycline for the treatment of bipolar depression: Effects on cortical glutathione and oxidative stress in vivo. Journal of Affective Disorders. 230: 56-64. PMID 29407539 DOI: 10.1016/J.Jad.2017.12.067 |
0.466 |
|
| 2018 |
Morris L, Costi S, Collins AB, Van Dam NT, Kundu P, Stern E, Russo S, Murrough JW. F163. Inflammation is Associated With Mesolimbic Reward Circuitry in Major Depression Biological Psychiatry. 83: S302. DOI: 10.1016/J.Biopsych.2018.02.777 |
0.379 |
|
| 2018 |
Grehl M, Van Dam N, Murrough J. F142. Effect of Treatment Resistance Status on Whole Brain Voxel-Based Morphometry in Major Depressive Disorder Biological Psychiatry. 83: S293. DOI: 10.1016/J.Biopsych.2018.02.756 |
0.44 |
|
| 2018 |
Tan A, Costi S, Morris L, Van Dam N, Murrough J. T131. KNCQ Channel Opener Ezogabine_x000B_as a Treatment for Depression: A Preliminary Resting State fMRI Analysis Biological Psychiatry. 83: S179. DOI: 10.1016/J.Biopsych.2018.02.467 |
0.641 |
|
| 2018 |
Hoch M, Collins KA, Doucet GE, Moser DA, Huryk KM, DeWilde KE, Fleysher L, Murrough JW, Frangou S, Iacoviello BM, Charney DS. T129. Brain Connectivity Changes Associated With a Cognitive-Emotional Training Intervention for Depression Biological Psychiatry. 83: S178. DOI: 10.1016/J.Biopsych.2018.02.465 |
0.338 |
|
| 2018 |
Nasca C, Bigio B, Lee F, Zelli D, Young S, Lau T, Issler O, Menard C, Murrough J, Kocsis J, Russo S, Nestler E, Rasgon N, McEwen B. 86. Role of the Epigenetic Agent Acetyl-L-Carnitine as Gating Biomarker in Depression and Influences of Childhood Trauma Biological Psychiatry. 83. DOI: 10.1016/J.Biopsych.2018.02.103 |
0.373 |
|
| 2018 |
Murrough J, Tan A, Morris L, Costi S, Van Dam N, Stern E, Nestler E, Han M. 65. From Stress Resilience to Novel Therapeutics: KCNQ Channel Openers and Other Approaches Emerging From Translational Neuroscience Biological Psychiatry. 83: S27. DOI: 10.1016/J.Biopsych.2018.02.082 |
0.574 |
|
| 2017 |
Sayed S, Van Dam NT, Horn SR, Kautz MM, Parides M, Costi S, Collins KA, Iacoviello B, Iosifescu DV, Mathé AA, Southwick SM, Feder A, Charney DS, Murrough JW. A randomized dose-ranging study of neuropeptide Y in patients with posttraumatic stress disorder. The International Journal of Neuropsychopharmacology. PMID 29186416 DOI: 10.1093/Ijnp/Pyx109 |
0.664 |
|
| 2017 |
Murrough JW, Charney DS. Corticotropin-Releasing Factor Type 1 Receptor Antagonists for Stress-Related Disorders: Time to Call It Quits? Biological Psychiatry. 82: 858-860. PMID 29129198 DOI: 10.1016/J.Biopsych.2017.10.012 |
0.301 |
|
| 2017 |
Homan P, Lin Q, Murrough JW, Soleimani L, Bach DR, Clem RL, Schiller D. Prazosin during threat discrimination boosts memory of the safe stimulus. Learning & Memory (Cold Spring Harbor, N.Y.). 24: 597-601. PMID 29038221 DOI: 10.1101/Lm.045898.117 |
0.305 |
|
| 2017 |
Fava M, Freeman MP, Flynn M, Hoeppner BB, Shelton R, Iosifescu DV, Murrough JW, Mischoulon D, Cusin C, Rapaport M, Dunlop BW, Trivedi MH, Jha M, Sanacora G, Hermes G, et al. Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD). Brain Stimulation. PMID 29030111 DOI: 10.1016/J.Brs.2017.09.010 |
0.41 |
|
| 2017 |
Murrough JW, Wade E, Sayed S, Ahle G, Kiraly DD, Welch A, Collins KA, Soleimani L, Iosifescu DV, Charney DS. Dextromethorphan/quinidine pharmacotherapy in patients with treatment resistant depression: A proof of concept clinical trial. Journal of Affective Disorders. 218: 277-283. PMID 28478356 DOI: 10.1016/J.Jad.2017.04.072 |
0.482 |
|
| 2017 |
Kiraly DD, Horn SR, Van Dam NT, Costi S, Schwartz J, Kim-Schulze S, Patel M, Hodes GE, Russo SJ, Merad M, Iosifescu DV, Charney DS, Murrough JW. Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome. Translational Psychiatry. 7: e1065. PMID 28323284 DOI: 10.1038/Tp.2017.31 |
0.391 |
|
| 2017 |
Murrough JW, Abdallah CG, Mathew SJ. Targeting glutamate signalling in depression: progress and prospects. Nature Reviews. Drug Discovery. PMID 28303025 DOI: 10.1038/Nrd.2017.16 |
0.474 |
|
| 2017 |
Tawakol A, Ishai A, Takx RA, Figueroa AL, Ali A, Kaiser Y, Truong QA, Solomon CJ, Calcagno C, Mani V, Tang CY, Mulder WJ, Murrough JW, Hoffmann U, Nahrendorf M, et al. Relation between resting amygdalar activity and cardiovascular events: a longitudinal and cohort study. Lancet (London, England). PMID 28088338 DOI: 10.1016/S0140-6736(16)31714-7 |
0.574 |
|
| 2017 |
Murrough J, Sayed S, Van Dam N, Horn S, Kautz M, Parides M, Iacoviello B, Costi S, Collins K, Iosifescu D, Southwick S, Mathé A, Feder A, Charney D. 171. A Randomized Controlled Dose-Ranging Study of Intranasal Administration of Neuropeptide Y in Patients with Posttraumatic Stress Disorder Biological Psychiatry. 81: S71. DOI: 10.1016/J.Biopsych.2017.02.184 |
0.344 |
|
| 2016 |
Kautz M, Charney DS, Murrough JW. Neuropeptide Y, resilience, and PTSD therapeutics. Neuroscience Letters. PMID 27913193 DOI: 10.1016/J.Neulet.2016.11.061 |
0.382 |
|
| 2016 |
Abdallah CG, Averill LA, Collins KA, Geha P, Schwartz J, Averill C, DeWilde KE, Wong E, Anticevic A, Tang CY, Iosifescu DV, Charney DS, Murrough JW. Ketamine Treatment and Global Brain Connectivity in Major Depression. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 27604566 DOI: 10.1038/Npp.2016.186 |
0.459 |
|
| 2016 |
Murrough JW. Ketamine for Depression: An Update. Biological Psychiatry. 80: 416-8. PMID 27565540 DOI: 10.1016/J.Biopsych.2016.07.005 |
0.44 |
|
| 2016 |
Friedman AK, Juarez B, Ku SM, Zhang H, Calizo RC, Walsh JJ, Chaudhury D, Zhang S, Hawkins A, Dietz DM, Murrough JW, Ribadeneira M, Wong EH, Neve RL, Han MH. KCNQ channel openers reverse depressive symptoms via an active resilience mechanism. Nature Communications. 7: 11671. PMID 27216573 DOI: 10.1038/Ncomms11671 |
0.452 |
|
| 2016 |
Murrough JW, Abdallah CG, Anticevic A, Collins KA, Geha P, Averill LA, Schwartz J, DeWilde KE, Averill C, Jia-Wei Yang G, Wong E, Tang CY, Krystal JH, Iosifescu DV, Charney DS. Reduced global functional connectivity of the medial prefrontal cortex in major depressive disorder. Human Brain Mapping. PMID 27144347 DOI: 10.1002/Hbm.23235 |
0.46 |
|
| 2016 |
Singh JB, Fedgchin M, Daly EJ, De Boer P, Cooper K, Lim P, Pinter C, Murrough JW, Sanacora G, Shelton RC, Kurian B, Winokur A, Fava M, Manji H, Drevets WC, et al. A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. The American Journal of Psychiatry. appiajp201616010037. PMID 27056608 DOI: 10.1176/Appi.Ajp.2016.16010037 |
0.448 |
|
| 2016 |
Schwartz J, Murrough JW, Iosifescu DV. Ketamine for treatment-resistant depression: recent developments and clinical applications. Evidence-Based Mental Health. PMID 27053196 DOI: 10.1136/Eb-2016-102355 |
0.499 |
|
| 2015 |
Soleimani L, Welch A, Murrough JW. "Does Ketamine Have Rapid Anti-Suicidal Ideation Effects?" Current Treatment Options in Psychiatry. 2: 383-393. PMID 26918229 DOI: 10.1007/S40501-015-0065-2 |
0.34 |
|
| 2015 |
Costi S, Van Dam NT, Murrough JW. Current Status of Ketamine and Related Therapies for Mood and Anxiety Disorders. Current Behavioral Neuroscience Reports. 2: 216-225. PMID 26783510 DOI: 10.1007/S40473-015-0052-3 |
0.711 |
|
| 2015 |
Lener MS, Kundu P, Wong E, Dewilde KE, Tang CY, Balchandani P, Murrough JW. Cortical abnormalities and association with symptom dimensions across the depressive spectrum. Journal of Affective Disorders. 190: 529-536. PMID 26571102 DOI: 10.1016/J.Jad.2015.10.027 |
0.437 |
|
| 2015 |
Murrough JW, Soleimani L, DeWilde KE, Collins KA, Lapidus KA, Iacoviello BM, Lener M, Kautz M, Kim J, Stern JB, Price RB, Perez AM, Brallier JW, Rodriguez GJ, Goodman WK, et al. Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychological Medicine. 1-10. PMID 26266877 DOI: 10.1017/S0033291715001506 |
0.411 |
|
| 2015 |
Murrough JW, Yaqubi S, Sayed S, Charney DS. Emerging drugs for the treatment of anxiety. Expert Opinion On Emerging Drugs. 20: 393-406. PMID 26012843 DOI: 10.1517/14728214.2015.1049996 |
0.357 |
|
| 2015 |
Murrough JW. Glutamate NMDA receptor modulators for the treatment of depression: trials and tribulations. Psychopharmacology. 232: 1497-9. PMID 25752888 DOI: 10.1007/S00213-015-3888-Z |
0.409 |
|
| 2015 |
Murrough JW, Collins KA, Fields J, DeWilde KE, Phillips ML, Mathew SJ, Wong E, Tang CY, Charney DS, Iosifescu DV. Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder. Translational Psychiatry. 5: e509. PMID 25689570 DOI: 10.1038/Tp.2015.10 |
0.438 |
|
| 2015 |
DeWilde KE, Levitch CF, Murrough JW, Mathew SJ, Iosifescu DV. The promise of ketamine for treatment-resistant depression: current evidence and future directions. Annals of the New York Academy of Sciences. 1345: 47-58. PMID 25649308 DOI: 10.1111/Nyas.12646 |
0.445 |
|
| 2015 |
Feder A, Murrough JW. Ketamine for posttraumatic stress disorder--reply. Jama Psychiatry. 72: 95-6. PMID 25564791 DOI: 10.1001/Jamapsychiatry.2014.1751 |
0.343 |
|
| 2015 |
Murrough JW, Burdick KE, Levitch CF, Perez AM, Brallier JW, Chang LC, Foulkes A, Charney DS, Mathew SJ, Iosifescu DV. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 40: 1084-90. PMID 25374095 DOI: 10.1038/Npp.2014.298 |
0.476 |
|
| 2015 |
Wan LB, Levitch CF, Perez AM, Brallier JW, Iosifescu DV, Chang LC, Foulkes A, Mathew SJ, Charney DS, Murrough JW. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. The Journal of Clinical Psychiatry. 76: 247-52. PMID 25271445 DOI: 10.4088/Jcp.13M08852 |
0.42 |
|
| 2015 |
Costi S, Hodes G, Schwartz J, Horn S, Collins K, Iosifescu D, Russo S, Murrough J. P.1.f.020 Association between peripheral interleukin 6 and brain response to positive stimuli in a depressive spectrum European Neuropsychopharmacology. 25: S235-S236. DOI: 10.1016/S0924-977X(15)30257-1 |
0.368 |
|
| 2014 |
Lapidus KA, Levitch CF, Perez AM, Brallier JW, Parides MK, Soleimani L, Feder A, Iosifescu DV, Charney DS, Murrough JW. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biological Psychiatry. 76: 970-6. PMID 24821196 DOI: 10.1016/J.Biopsych.2014.03.026 |
0.478 |
|
| 2014 |
Iacoviello BM, Wu G, Alvarez E, Huryk K, Collins KA, Murrough JW, Iosifescu DV, Charney DS. Cognitive-emotional training as an intervention for major depressive disorder. Depression and Anxiety. 31: 699-706. PMID 24753225 DOI: 10.1002/Da.22266 |
0.349 |
|
| 2014 |
Feder A, Parides MK, Murrough JW, Perez AM, Morgan JE, Saxena S, Kirkwood K, Aan Het Rot M, Lapidus KA, Wan LB, Iosifescu D, Charney DS. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. Jama Psychiatry. 71: 681-8. PMID 24740528 DOI: 10.1001/Jamapsychiatry.2014.62 |
0.424 |
|
| 2014 |
Lapidus KA, Gabbay V, Mao X, Johnson A, Murrough JW, Mathew SJ, Shungu DC. In vivo (1)H MRS study of potential associations between glutathione, oxidative stress and anhedonia in major depressive disorder. Neuroscience Letters. 569: 74-9. PMID 24704328 DOI: 10.1016/J.Neulet.2014.03.056 |
0.451 |
|
| 2014 |
Iacoviello BM, Wu G, Abend R, Murrough JW, Feder A, Fruchter E, Levinstein Y, Wald I, Bailey CR, Pine DS, Neumeister A, Bar-Haim Y, Charney DS. Attention bias variability and symptoms of posttraumatic stress disorder. Journal of Traumatic Stress. 27: 232-9. PMID 24604631 DOI: 10.1002/Jts.21899 |
0.335 |
|
| 2014 |
Haile CN, Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Foulkes A, Iqbal S, Mahoney JJ, De La Garza R, Charney DS, Newton TF, Mathew SJ. Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 17: 331-6. PMID 24103211 DOI: 10.1017/S1461145713001119 |
0.38 |
|
| 2014 |
Singh J, Fedgchin M, Daly E, Boer PD, Cooper K, Lim P, Pinter C, Murrough J, Sanacora G, Shelton R, Kurian B, Winokur A, Fava M, Manji H, Drevets W, et al. P.2.b.017 Onset of efficacy of ketamine in treatment-resistant depression: a double-blind, randomised, placebo-controlled, dose frequency study European Neuropsychopharmacology. 24. DOI: 10.1016/S0924-977X(14)70618-2 |
0.395 |
|
| 2014 |
Sayed S, Horn SR, Murrough JW. Current Treatments for Anxiety and Obsessive-Compulsive Disorders Current Treatment Options in Psychiatry. 1: 248-262. DOI: 10.1007/S40501-014-0020-7 |
0.416 |
|
| 2013 |
Murrough JW, Wan LB, Iacoviello B, Collins KA, Solon C, Glicksberg B, Perez AM, Mathew SJ, Charney DS, Iosifescu DV, Burdick KE. Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response. Psychopharmacology. PMID 24022236 DOI: 10.1007/S00213-013-3255-X |
0.461 |
|
| 2013 |
Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, Iqbal S, Pillemer S, Foulkes A, Shah A, Charney DS, Mathew SJ. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. The American Journal of Psychiatry. 170: 1134-42. PMID 23982301 DOI: 10.1176/Appi.Ajp.2013.13030392 |
0.434 |
|
| 2013 |
Lapidus KA, Soleimani L, Murrough JW. Novel glutamatergic drugs for the treatment of mood disorders. Neuropsychiatric Disease and Treatment. 9: 1101-12. PMID 23976856 DOI: 10.2147/Ndt.S36689 |
0.43 |
|
| 2013 |
Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, aan het Rot M, Collins KA, Mathew SJ, Charney DS, Iosifescu DV. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biological Psychiatry. 74: 250-6. PMID 22840761 DOI: 10.1016/J.Biopsych.2012.06.022 |
0.434 |
|
| 2013 |
Murrough J, Iosifescu D, Chang L, Al Jurdi R, Green C, Perez A, Iqbal S, Pillemer S, Foulkes A, Mathew S. P.2.f.028 Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site, randomised controlled trial European Neuropsychopharmacology. 23: S411-S412. DOI: 10.1016/S0924-977X(13)70651-5 |
0.406 |
|
| 2012 |
Kellner CH, Greenberg RM, Murrough JW, Bryson EO, Briggs MC, Pasculli RM. ECT in treatment-resistant depression. The American Journal of Psychiatry. 169: 1238-44. PMID 23212054 DOI: 10.1176/Appi.Ajp.2012.12050648 |
0.433 |
|
| 2012 |
Russo SJ, Murrough JW, Han MH, Charney DS, Nestler EJ. Neurobiology of resilience. Nature Neuroscience. 15: 1475-84. PMID 23064380 DOI: 10.1038/Nn.3234 |
0.32 |
|
| 2012 |
Murrough JW, Charney DS. Is there anything really novel on the antidepressant horizon? Current Psychiatry Reports. 14: 643-9. PMID 22996298 DOI: 10.1007/S11920-012-0321-8 |
0.454 |
|
| 2012 |
Neumeister A, Normandin MD, Murrough JW, Henry S, Bailey CR, Luckenbaugh DA, Tuit K, Zheng MQ, Galatzer-Levy IR, Sinha R, Carson RE, Potenza MN, Huang Y. Positron emission tomography shows elevated cannabinoid CB1 receptor binding in men with alcohol dependence. Alcoholism, Clinical and Experimental Research. 36: 2104-9. PMID 22551199 DOI: 10.1111/J.1530-0277.2012.01815.X |
0.474 |
|
| 2012 |
Mathew SJ, Shah A, Lapidus K, Clark C, Jarun N, Ostermeyer B, Murrough JW. Ketamine for treatment-resistant unipolar depression: current evidence. Cns Drugs. 26: 189-204. PMID 22303887 DOI: 10.2165/11599770-000000000-00000 |
0.475 |
|
| 2012 |
Shungu DC, Weiduschat N, Murrough JW, Mao X, Pillemer S, Dyke JP, Medow MS, Natelson BH, Stewart JM, Mathew SJ. Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology. Nmr in Biomedicine. 25: 1073-87. PMID 22281935 DOI: 10.1002/Nbm.2772 |
0.358 |
|
| 2012 |
Shungu D, Weidschat N, Mao X, Pillemer S, Murrough J, Mathew S. P-801 - In vivo neuroimaging evidence of oxidative stress in major depressive disorder European Psychiatry. 27: 1. DOI: 10.1016/S0924-9338(12)74968-4 |
0.411 |
|
| 2011 |
Murrough JW. Ketamine as a novel antidepressant: from synapse to behavior. Clinical Pharmacology and Therapeutics. 91: 303-9. PMID 22205190 DOI: 10.1038/Clpt.2011.244 |
0.378 |
|
| 2011 |
Murrough JW, Czermak C, Henry S, Nabulsi N, Gallezot JD, Gueorguieva R, Planeta-Wilson B, Krystal JH, Neumaier JF, Huang Y, Ding YS, Carson RE, Neumeister A. The effect of early trauma exposure on serotonin type 1B receptor expression revealed by reduced selective radioligand binding. Archives of General Psychiatry. 68: 892-900. PMID 21893657 DOI: 10.1001/Archgenpsychiatry.2011.91 |
0.34 |
|
| 2011 |
Murrough JW, Huang Y, Hu J, Henry S, Williams W, Gallezot JD, Bailey CR, Krystal JH, Carson RE, Neumeister A. Reduced amygdala serotonin transporter binding in posttraumatic stress disorder. Biological Psychiatry. 70: 1033-8. PMID 21855859 DOI: 10.1016/J.Biopsych.2011.07.003 |
0.39 |
|
| 2011 |
Murrough JW, Iacoviello B, Neumeister A, Charney DS, Iosifescu DV. Cognitive dysfunction in depression: Neurocircuitry and new therapeutic strategies Neurobiology of Learning and Memory. 96: 553-563. PMID 21704176 DOI: 10.1016/J.Nlm.2011.06.006 |
0.38 |
|
| 2011 |
Murrough JW, Perez AM, Mathew SJ, Charney DS. A case of sustained remission following an acute course of ketamine in treatment-resistant depression. The Journal of Clinical Psychiatry. 72: 414-5. PMID 21450159 DOI: 10.4088/Jcp.10L06447Blu |
0.403 |
|
| 2011 |
Murrough JW, Neumeister A. The serotonin 1B receptor: a new target for depression therapeutics? Biological Psychiatry. 69: 714-5. PMID 21447414 DOI: 10.1016/J.Biopsych.2011.02.020 |
0.378 |
|
| 2011 |
Mathew SJ, Vythilingam M, Murrough JW, Zarate CA, Feder A, Luckenbaugh DA, Kinkead B, Parides MK, Trist DG, Bani MS, Bettica PU, Ratti EM, Charney DS. A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 21: 221-9. PMID 21194898 DOI: 10.1016/J.Euroneuro.2010.11.012 |
0.328 |
|
| 2011 |
Murrough JW, Henry S, Hu J, Gallezot JD, Planeta-Wilson B, Neumaier JF, Neumeister A. Reduced ventral striatal/ventral pallidal serotonin1B receptor binding potential in major depressive disorder. Psychopharmacology. 213: 547-53. PMID 20480149 DOI: 10.1007/S00213-010-1881-0 |
0.333 |
|
| 2011 |
Murrough JW, Czermak C, Henry S, Nabulsi N, Gallezot J, Gueorguieva R, Planeta-Wilson B, Krystal JH, Neumaier JF, Huang Y, Ding Y, Carson RE, Neumeister A. Age at first trauma is associated with serotonin 1B receptor reductions and comorbid depression in posttraumatic stress disorder F1000research. 2. DOI: 10.7490/F1000Research.1190.1 |
0.337 |
|
| 2011 |
Brodman DM, Clark CT, Murrough JW, Mathew SJ, Harvey PD. The implications of neurocognitive defi cits in posttraumatic stress disorder Psychiatric Annals. 41: 408-412. DOI: 10.3928/00485713-20110727-07 |
0.341 |
|
| 2011 |
Murrough JW, Gallo JM, Collins KA, Aan Het Rot M, Charney DS. Reply to: Dose- and exposure-response to ketamine in depression Biological Psychiatry. 70: e11-e12. DOI: 10.1016/J.Biopsych.2011.02.018 |
0.389 |
|
| 2010 |
Murrough JW, Mao X, Collins KA, Kelly C, Andrade G, Nestadt P, Levine SM, Mathew SJ, Shungu DC. Increased ventricular lactate in chronic fatigue syndrome measured by 1H MRS imaging at 3.0 T. II: comparison with major depressive disorder. Nmr in Biomedicine. 23: 643-50. PMID 20661876 DOI: 10.1002/Nbm.1512 |
0.373 |
|
| 2010 |
aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, Mathew SJ. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biological Psychiatry. 67: 139-45. PMID 19897179 DOI: 10.1016/J.Biopsych.2009.08.038 |
0.411 |
|
| 2010 |
Mathew SJ, Murrough JW, aan het Rot M, Collins KA, Reich DL, Charney DS. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 13: 71-82. PMID 19288975 DOI: 10.1017/S1461145709000169 |
0.416 |
|
| 2009 |
Price RB, Shungu DC, Mao X, Nestadt P, Kelly C, Collins KA, Murrough JW, Charney DS, Mathew SJ. Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder. Biological Psychiatry. 65: 792-800. PMID 19058788 DOI: 10.1016/J.Biopsych.2008.10.025 |
0.406 |
|
| 2006 |
Epstein J, Pan H, Kocsis JH, Yang Y, Butler T, Chusid J, Hochberg H, Murrough J, Strohmayer E, Stern E, Silbersweig DA. Lack of ventral striatal response to positive stimuli in depressed versus normal subjects. The American Journal of Psychiatry. 163: 1784-90. PMID 17012690 DOI: 10.1176/Ajp.2006.163.10.1784 |
0.399 |
|
| Show low-probability matches. |